검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | BAY94-9343 (Expansion) |
Overview Company | Bayer |
Overview Modality | ADC |
Overview Target | Oncology |
Overview Indication | Oncology |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | and potential as a precision immunomodulator that can selectively expand and reprogram T cells |
MoA Biomarker | biomarkers, neurophysiological function, bladder outcomes and spinal cord imaging metrics |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Safety and early efficacy of iPSC-derived motor neuron progenitor cells in subacute spinal cord injury: protocol for a phase I, multicentre, open-label, single-arm trial.. Spinal cord injury (SCI) frequently results in severe neurological impairment due to neural tissue destruction and scarring, representing a substantial and increasing global health burden. Current standard treatments primarily f… |
Toxicology CRS | grade 1 |
Clinical Primary efficacy | ORR 41.7% |
Clinical ORR | 41.7% |
Clinical PFS | 10.9 |
Clinical OS | 32.8 |
Clinical Result source | ClinicalTrials.gov NCT01625286 |
Clinical Data Tier / Score | A · 51 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | BAY94-9343 (Expansion) |
Overview Company | Bayer |
Overview Modality | ADC |
Overview Target | Oncology |
Overview Indication | Oncology |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | and potential as a precision immunomodulator that can selectively expand and reprogram T cells |
MoA Biomarker | biomarkers, neurophysiological function, bladder outcomes and spinal cord imaging metrics |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Safety and early efficacy of iPSC-derived motor neuron progenitor cells in subacute spinal cord injury: protocol for a phase I, multicentre, open-label, single-arm trial.. Spinal cord injury (SCI) frequently results in severe neurological impairment due to neural tissue destruction and scarring, representing a substantial and increasing global health burden. Current standard treatments primarily f… |
Toxicology CRS | grade 1 |
Clinical Primary efficacy | ORR 41.7% |
Clinical ORR | 41.7% |
Clinical PFS | 10.9 |
Clinical OS | 32.8 |
Clinical Result source | ClinicalTrials.gov NCT01625286 |
Clinical Data Tier / Score | A · 51 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교